<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446758</url>
  </required_header>
  <id_info>
    <org_study_id>14511</org_study_id>
    <nct_id>NCT00446758</nct_id>
  </id_info>
  <brief_title>Trial of Zinc and HIV Progression in Children</brief_title>
  <official_title>Trial of Zinc and HIV Progression in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Muhimbili University of Health and Allied Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard School of Public Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine whether daily oral zinc supplementation to HIV-infected Tanzanian preschool
      children reduces diarrheal and respiratory morbidity, delays HIV disease progression, and
      improves growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to examine whether daily oral zinc supplementation to
      HIV-infected Tanzanian preschool children reduces diarrheal and respiratory morbidity, delays
      HIV disease progression, and improves growth.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity from respiratory and diarrheal infections, HIV disease progression</measure>
    <time_frame>every 4 to 6 months until the end of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>growth in height and weight</measure>
    <time_frame>every 4 to 6 months until the end of follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zinc (as zinc sulphate) 12.5 mg orally per day (6.25 mg in children &lt; 12 mo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>zinc effervescent tablets: 6.25mg to infants â‰¤12 months and 12.5 mg to children &gt; 12 months.</description>
    <arm_group_label>Zinc</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV Infected Children under 60 months of age presenting at HIV treatment clinics in
             Dar es Salaam, Tanzania

        Exclusion Criteria:

        Eligible for ART: CD4 cell counts &lt; 20% or above pediatric clinical stage of HIV disease 3
        according to WHO staging system.

        Severe acute malnutrition; Major congenital malformations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Villamor, MD, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Muhimbili University College of Health Sciences</name>
      <address>
        <city>Dar es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2007</study_first_submitted>
  <study_first_submitted_qc>March 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2007</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harvard School of Public Health</investigator_affiliation>
    <investigator_full_name>Eduardo Villamor</investigator_full_name>
    <investigator_title>Adjunct Associate Professor of International Nutrition</investigator_title>
  </responsible_party>
  <keyword>Zinc</keyword>
  <keyword>HIV</keyword>
  <keyword>Infants</keyword>
  <keyword>Children</keyword>
  <keyword>Morbidity</keyword>
  <keyword>Child health outcomes</keyword>
  <keyword>treatment naive</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

